Silicon Ranch Corporation, the U.S. solar platform for Shell and one of America's largest independent solar power producers, announced the launch of Regenerative Energy, a verified third-party product that combines clean electricity generation with carbon sequesteration, ecosystem restoration, and rural economic revitalization. To develop its Regenerative Energy program, Silicon Ranch has partnered with renowned regenerative ranchers and local farmers, who are working with Silicon Ranch to deploy holistic land use practices on solar farms across the country.
A new survey of medical researchers finds many have the desire to streamline clinical trial processes. All researchers surveyed reported the need to improve information exchange, driven by the necessity to reduce manual processes, improve collaboration as well as increase visibility and oversight during trials, according to the vendor.
The Senate Finance Committee is still negotiating major pieces of legislation to lower drug costs, and leaders are staying mum on what's holding up the bill as they seek to cut prices within Medicare Part B and Part D. The panel's Ranking Democrat Ron Wyden of Oregon said he and Senate Finance Committee Chair, Chuck Grassley (R-Iowa), are meeting daily and sometimes several times a day about the proposals.
University labs are one of the biggest engines of innovative healthcare technology in the country. But translating those discoveries from the campus to the consumer poses unique business challenges around licensing. A panel at the WSGR Medical Device Conference in San Francisco delved into the specifics around what often sinks the relationship between the two stakeholders.
The U.S. Food and Drug Administration has released more than 20 years of reports detailing adverse events involving medical devices, ending a program that allowed some manufacturers to keep safety issues from the public. The agency announced June 21 it has made publicly available approximately six million adverse event reports dating back to 1990 that were not previously included in federal databases. Those reports were exempted under the FDA's Alternative Summary Reporting program.